45
Participants
Start Date
June 30, 2008
Primary Completion Date
May 31, 2012
Study Completion Date
August 31, 2013
Taliglucerase alfa
Intravenous infusion every 2 weeks
Morningside Medi-Clinic, Morningside
Neurogenetics, NYU at Rivergate, New York
Department of Human Genetics, Emory University School of Medicine, Decatur
Rambam Medical Center, Haifa
Hospital Universitario Miguel Servet, Zaragoza
Bone Marrow Transplant Service, The Royal Melbourne Hospital, Parkville
Pontificia Universidad Catolica de Chile, Santiago
Shaare Zedek Medical Center, Jerusalem
Lysosomal Disorders Service, Addenbrookes Hospital NHS Trust, Cambridge
Mount Sinai Hospital, Toronto
Royal Free Hospital, London
Lead Sponsor
Pfizer
INDUSTRY